# Cyteir Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyteir-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Lexington, US
- Website: www.cyteir.com
- Total disclosed funding: $129M
- Latest round: Series C (Feb 5, 2021)
- Investors on record: 14

## About

Based in Massachusetts, US, Cyteir Therapeutics, Inc. was founded in 2012 by co-founders Tim Romberger and Kevin Mills. The company raised its first funding in November 2015 and has a total of 5 funding rounds as of June 2021. In 2020, the company advanced its clinical trial to phase 1 for its inhibitor advancing to once-daily dosing. Cyteir filed on the NASDAQ to become a public company in March 2021.

Cyteir employs an integrated drug development platform to create a pipeline of small molecule medicines with a variety of possible disease state applications by modulating the imbalance between DNA damage and repair for therapeutic impact. It specializes in treating a variety of hematological cancers, solid tumors, and chronic autoimmune diseases.

The company plans to continue to develop its synthetic lethality platform to find new targets that inhibit DNA damage repair, and to continue to evaluate the safety and tolerability of CYT-0851 during its phase 2 and future studies.

## Funding rounds

- Series C, Feb 5, 2021, $80M — Venrock, Novo Holdings, OUP (Osage University Partners), Lightstone Ventures, RA Capital Management, Acuta Capital Partners, Ally Bridge Group, Droia Ventures, Janus Henderson Investors, Avidity Partners, Ample Plus Fund Partnership LTD, CaaS Capital Management
- Series B, Oct 15, 2019, $20M — Venrock, Novo Holdings, OUP (Osage University Partners), Lightstone Ventures, Bristol-Myers Squibb Company, Droia Ventures
- Series B, Mar 8, 2018, $29M — Venrock, OUP (Osage University Partners), Celgene, Lightstone Ventures, Droia Ventures

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series B, Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B, Series C
- Celgene — Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series B, Series C
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series B, Series C
- Novo Holdings — Series B, Series C
- Bristol-Myers Squibb Company — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Acuta Capital Partners (https://capitalatlas.ai/funds/acuta-capital-partners) — Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- Janus Henderson Investors — Series C
- Avidity Partners — Series C
- Ample Plus Fund Partnership LTD — Series C
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series C